Treatment options set to expand for patients with imatinib-resistant chronic myeloid leukaemia

The Pharmaceutical Journal Group

首页> 外文期刊>The pharmaceutical journal >Treatment options set to expand for patients with imatinib-resistant chronic myeloid leukaemia

【24h】

Treatment options set to expand for patients with imatinib-resistant chronic myeloid leukaemia

机译：伊马替尼耐药的慢性粒细胞白血病患者的治疗选择将扩大

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Dasatinib and nilotinib,novel tyrosine kinase inhibitors currently in development,induce haematologic and cytogenetic responses in patients with imatinib-resistant leukaemias,two studies published this week in The New England Journal of Medicine reveal (2006;354: 2531 and 2542).

机译：达沙替尼和尼罗替尼，目前正在开发的新型酪氨酸激酶抑制剂，在伊马替尼耐药的白血病患者中可引起血液学和细胞遗传学反应，本周发表在《新英格兰医学杂志》上的两项研究显示（2006; 354：2531和2542）。

著录项

来源
《The pharmaceutical journal》 |2006年第7405期|共1页
作者
The Pharmaceutical Journal Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Treatment options set to expand for patients with imatinib-resistant chronic myeloid leukaemia [J] . The Pharmaceutical Journal Group The pharmaceutical journal . 2006,第7405期

机译：伊马替尼耐药的慢性粒细胞白血病患者的治疗选择将扩大
2. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia [J] . D Rea, E Raffoux, J-M Cayuela, Leukemia . 2009,第6期

机译：在达斯替尼治疗和自体外周血液干细胞移植患者患者中没有任何抗血清症治疗的持续重大分子反应耐用于伊替尼尿素髓细胞相慢性骨髓性白血病
3. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: A systematic review and economic evaluation [J] . LovemanE., CooperK., BryantJ., Health technology assessment: HTA . 2012,第23期

机译：达沙替尼，大剂量伊马替尼和尼罗替尼治疗伊马替尼耐药的慢性粒细胞白血病：系统评价和经济评价
4. Enhancement of the Immune Response to Chronic Myeloid Leukaemia via Controlled Treatment Scheduling [C] . H. Chang, A. Astolfi Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2009

机译：通过受控治疗调度增强免疫应答对慢性髓性白血病的影响
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Dasatinib high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. [O] . E Loveman, K Cooper, J Bryant, -1

机译：达沙替尼高剂量伊马替尼和尼罗替尼用于治疗伊马替尼耐药的慢性髓性白血病的系统评价和经济评价。
7. Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia [O] . D Rea, E Raffoux, J-M Cayuela, 2009

机译：在达斯替尼治疗和自体外周血液干细胞移植患者患者中没有任何抗血清症治疗的持续重大分子反应耐用于伊替尼尿素髓细胞相慢性骨髓性白血病

Treatment options set to expand for patients with imatinib-resistant chronic myeloid leukaemia

摘要

著录项

相似文献

相关主题

期刊订阅